Want to talk to a product specialist ?
Book an appointment
Register to receive our 5-email series about QUVIVIQ™

Healthcare Professional Portal
Want to talk to a product specialist ?
Book an appointment
Register to receive our 5-email series about QUVIVIQ™
Our Services
PI & AE
Prescribing information and adverse event reporting information can be accessed using the PI & AE button at the side.

Discover QUVIVIQ™▼ (daridorexant), as a treatment option for adult patients with chronic insomnia1,2

  • NICE recommended for primary care in chronic insomnia3
  • SMC accepted for restricted use within NHSScotland4

QUVIVIQ™ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1

* For adults with chronic insomnia with symptoms lasting for 3 nights or more per week3 for at least 3 months and whose daytime functioning is considerably affected, only if CBT-I has been tried but not worked or is unavailable or unsuitable. The length of treatment should be for as short as possible.3,4
What is QUVIVIQ™?
What is QUVIVIQ™?
How does QUVIVIQ™ work?
How does QUVIVIQ™ work?
Read about safety and efficacy
Read about safety and efficacy

Chronic Insomnia Topics

Diagnosing Chronic Insomnia

Browse Chronic Insomnia Patient Profiles

Discover the Different Chronic Insomnia Patient Profiles

  • Explore Patient Profiles

NICE recommends Daridorexant for treating long-term insomnia

Read the evidence-based recommendations on Daridorexant (QUVIVIQ™) for treating long-term insomnia in adults.

Read the evidence-based recommendations on Daridorexant (QUVIVIQ™) for treating long-term insomnia in adults.

  • Read NICE Recommendations

Understanding Chronic Insomnia

Deepen Your Understanding of Chronic Insomnia

Explore a self-led course on chronic insomnia through interactive modules and case studies.

  • Start E-Learning

NICE recommends Daridorexant for treating long-term insomnia

Read the evidence-based recommendations on Daridorexant (QUVIVIQ™) for treating long-term insomnia in adults.

  • Read NICE Recommandations

Practical Resources

Discuss key domains to uncover your patients’ insomnia

  • Download the Resource

Patient support material from Idorsia Pharmaceuticals UK Ltd.

Summary of the two Phase 3 studies on daridorexant

  • Read the Summary

Promotional material from Idorsia Pharmaceuticals UK Ltd.

Overactive wake signalling as a cause of chronic insomnia

  • Watch the Video

Promotional material from Idorsia Pharmaceuticals UK Ltd.

Visit Our Insomnia Dedicated Resource Center

Navigate through our collection of expert videos, engaging infographics, and essential downloads to better support your patients with chronic insomnia.

  • Access Resource Center

References

  1. QUVIVIQ™ Idorsia Pharmaceuticals LTD, Summary of Product Characteristics.
  2. Mignot E, et al. Lancet Neurol. 2022. 21(2); 125–139.
  3. NICE. TA922. Daridorexant for treating long-term insomnia, October 2023. Available at: https://www.nice.org.uk/guidance/ta922. Last accessed July 2024.
  4. SMC. SMC2611. Daridorexant film-coated tablets (Quviviq®). Available at: https://www.scottishmedicines.org.uk/media/8230/daridorexant-quviviq-final-march-2024-for-website.pdf. Last accessed April 2024

This information is intended for UK healthcare professionals.

Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.

UK-DA-00400 | Date of preparation: August 2024

Copyright © 2025 Idorsia Pharmaceuticals Ltd
Sign in

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Welcome back!

Please complete the form below to sign in.

You don’t have an account? 

Sign up

You are now leaving pro.idorsia.uk

You are now leaving pro.idorsia.uk. You will now be redirected to an independent third-party site that is maintained outside of this website.
You are now leaving pro.idorsia.uk. The linked website provides helpful information if you are having trouble sleeping. It is neither owned or controlled by Idorsia Pharmaceuticals Ltd. Idorsia accepts no responsibility for the content or services of the linked site.
Cancel
Go to link

UK-DA-00445 | Date of preparation: May 2024

Copyright ©2025 Idorsia Pharmaceuticals Ltd
Confirming your contact information and preferences means that you agree that we, Idorsia, manage your personal data in our Client Relationship Management system to document, customise, plan, and conduct our interactions with you and, to analyse and segment your interactions, interests, preferences, and scientific activities in order to interact with you in a way we think is most relevant to you. It also means that you agree that we will send you Idorsia standard or personalised medical, company or product related information and material via email based on your choices and on what we think is of interest to you. You further consent that we process your personal data for this. For more information about us, our processing of your personal data and your rights, please see our Privacy Notice.
Create an account
Access our in-depth e-learning resources on chronic insomnia
Title *
First name *
Last name *
Professional email *
Password *
Specialty *
Professional registration number *

Select below to keep informed of further resources:

You already have an account? 

Sign in

Gain access to resources on Chronic Insomnia​

Register to get access to:

  • Insightful videos
  • Patient resources
  • E-Learning programme
  • And details about us and our offerings